Peptide PilotPeptide Pilot

mg ↔ units

TB-500 mg to units converter

Set your TB-500 vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

2.000

units

80.0

mL

0.800

Concentration: 2.50 mg/mL (assumes a U-100 insulin syringe).

TB-500 is a synthetic fragment of the natural protein Thymosin Beta-4 that people use to support recovery from soft-tissue and tendon injuries. It works by promoting cell migration and new blood-vessel formation at injury sites, which is what allows damaged tissue to rebuild faster. Animal studies show meaningful acceleration of wound and tendon healing; controlled human data is limited. This page covers reconstitution math and how people typically log a loading-then-maintenance schedule.

How the TB-500 mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the TB-500 concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 2.5 mg/mL TB-500 solution, 2 mg comes out to 80 units, and 80 units comes out to 2 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 5 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for TB-500

TB-500 is a synthetic peptide fragment corresponding to the active region of Thymosin Beta-4, an exceptionally abundant protein found within the cytoplasm and nucleus of most human and animal cells. Specifically, it often represents the LKKTETQ amino acid sequence, which is believed to be central to the parent protein's primary biological function of sequestering actin monomers. Thymosin Beta-4 is widely distributed throughout the body and is upregulated during embryonic development and in response to injury. Consequently, its synthetic fragment, TB-500, has become a subject of focused scientific inquiry in contexts related to tissue repair, cellular regeneration, and inflammatory modulation, where research models often explore how this specific fragment can replicate the functional effects of the much larger, naturally-occurring 43-amino-acid protein.

The molecular characteristics of TB-500 distinguish it from many smaller peptides, notably in its larger size and an effective dose range measured in milligrams (mg) instead of micrograms (mcg). This larger magnitude has direct consequences for laboratory procedures, influencing how solutions are reconstituted, what diluent volumes are practical, and how doses are measured for administration. In personal-tracking logs, this peptide is most frequently documented with a weekly or twice-weekly cadence, sometimes following an initial 'loading' period of more frequent administration designed to reach a steady-state concentration more rapidly. It is also commonly logged alongside BPC-157, a combination where the two compounds' distinct mechanisms and cadences are viewed as complementary rather than competitive.

TB-500 mechanism in plain English

The proposed mechanism of TB-500 is directly inherited from its parent protein, Thymosin Beta-4, which functions as the primary G-actin-sequestering molecule inside cells. G-actin (globular actin) monomers are the fundamental building blocks of F-actin (filamentous actin), which forms the microfilaments of the dynamic cellular cytoskeleton. By binding to G-actin with a 1:1 stoichiometry, Thymosin Beta-4 controls the available pool of monomers and thus modulates the rate and spatial dynamics of actin polymerization. This intricate process of cytoskeletal rearrangement is fundamental to a cell's ability to change shape, exert force, move, and divide, making it a critical control point for cell motility and migration.

This specific actin-modulating activity is the molecular basis for the effects observed in research studies examining wound closure, inflammation, and tissue protection. For a cell to migrate—such as a keratinocyte moving into a wound bed, a fibroblast depositing extracellular matrix, or an endothelial cell forming a new blood vessel—it must be able to rapidly assemble and disassemble its actin cytoskeleton to crawl and navigate its environment. By influencing this core cellular machinery, TB-500 is studied for its potential to support these actin-dependent processes. This mechanism is biochemically distinct from pathways targeted by other peptides, such as those that directly stimulate angiogenic growth factors or activate specific G-protein coupled receptors, explaining its unique profile in research.

Tracking TB-500 unit counts

When implementing a twice-weekly protocol, the most important detail to log is the strict adherence to the chosen administration days to maintain a consistent interval. A common deviation is schedule drift, where a missed Thursday dose is taken on Friday, and the subsequent dose shifts from Monday to Tuesday, gradually extending the time between doses. To prevent this, a log should explicitly state the intended schedule (e.g., 'Monday/Thursday') and record the actual date and time of each dose. This rigorous documentation ensures that any observed outcomes can be correlated with a consistent and verifiable administration timeline.

Common TB-500 conversion mistakes

  • Assuming the same unit measurement as BPC-157 when they are stacked, leading to a significant under-dose of TB-500 due to its milligram-scale dosing.
  • Entering a 2.5 mg dose into a calculator field that defaults to micrograms (mcg), resulting in a miscalculation of several orders of magnitude.
  • Allowing a twice-weekly schedule to drift by a day each week, altering the dosing interval from a 3-day/4-day pattern to a 4-day/5-day pattern over time.
  • Using only 1 mL of diluent for a 10 mg vial and finding the resulting solution too concentrated to measure small dose adjustments precisely on a U-100 syringe.
  • Failing to log the 'loading' phase parameters separately from the 'maintenance' phase, making it difficult to analyze the distinct periods of the protocol later.

Frequently asked questions about TB-500 mg ↔ units

Why are TB-500 doses measured in milligrams (mg) while many others are in micrograms (mcg)?
The dosage scale is related to the peptide's molecular structure and the concentrations studied in research literature. TB-500 is a fragment of a larger, naturally abundant protein, and the quantities examined for biological activity are correspondingly higher than those for smaller synthetic peptides that act on highly sensitive receptors. This difference in magnitude necessitates using milligrams as the unit of measurement for accurate planning, calculation, and tracking.
If I use a 5 mg vial and 2 mL of diluent, how many units do I draw for a 2 mg dose?
With a 5 mg vial reconstituted with 2 mL of bacteriostatic water, the concentration becomes 2.5 mg per mL. To calculate a 2 mg dose, you would need 0.8 mL of the solution. On a U-100 insulin syringe, where 100 units equal 1 mL, 0.8 mL is equal to 80 units. Using a dose calculator is the most reliable way to convert your desired milligram dose into the correct syringe units.
What is the rationale behind a twice-weekly administration schedule?
The less frequent administration schedule, such as twice per week, documented in research logs for TB-500 is generally associated with a longer biological half-life compared to peptides requiring daily or more frequent dosing. This allows for sustained systemic levels to be maintained without the logistic complexity of daily administration. The specific interval (e.g., Monday/Thursday) is chosen to keep peptide concentrations relatively consistent throughout the week.
How does TB-500's mechanism differ from that proposed for BPC-157?
Research suggests they operate through different primary pathways. TB-500's proposed mechanism involves modulating actin dynamics, a fundamental intracellular process for cell structure and migration. In contrast, BPC-157 is primarily studied for its influence on the nitric oxide (NO) system and its effects on angiogenesis (the formation of new blood vessels), largely extracellular and signaling-based activities. Because these mechanisms are distinct, they are often studied in combination to observe their potentially complementary roles.
Is a 'loading phase' documented in research protocols?
Some logs and research reports document a 'loading phase,' characterized by more frequent or higher doses for an initial period, followed by a lower-dose 'maintenance phase.' The theory is to more rapidly elevate systemic concentrations to a steady state. However, other protocols begin directly with a maintenance-style cadence. Tracking logs show both approaches being used, and the decision to use a loading phase is a key variable to document when planning and reviewing a research cycle.
Can I pre-load syringes with TB-500 for a week?
Pre-loading syringes introduces additional stability variables, primarily concerning the interaction of the reconstituted peptide with the syringe materials over time. The stability of most peptides is best characterized in sterile glass vials, not in plastic syringes where factors like surface adsorption and interaction with the rubber plunger are unknown. For this reason, the standard practice documented is to draw each dose from the refrigerated vial immediately before administration to ensure consistency and minimize potential degradation.

Related on Peptide Pilot

Save your TB-500 vial in the app

Download on the App Store
Get the App